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We report 2 cases of babesiosis in immunocompetent 
patients in France. A severe inﬂ  uenza-like disease devel-
oped in both patients 2 weeks after they had been bitten 
by ticks. Diagnosis was obtained from blood smears, and 
Babesia divergens was identiﬁ  ed by PCR in 1 case. Babe-
siosis in Europe occurs in healthy patients, not only in sple-
nectomized patients.  
B
abesiosis, a tick-borne infectious disease that occurs 
worldwide, is caused by species of Babesia, an intra-
erythrocytic parasite (1). Babesia spp. parasites infect wild 
and domesticated animals and may cause a malaria-like 
syndrome. The ﬁ  rst human case was described in 1957 in 
a splenectomized Yugoslavian farmer who died (2). More 
than 100 Babesia species infect animals, but human infec-
tion has been associated with only a few species, mainly 
B. microti and B. divergens (1–3). B. microti parasites are 
transmitted by Ixodes scapularis ticks and infect rodents. 
Since 1957, these parasites have caused hundreds of hu-
man babesiosis cases in the United States, the most affected 
country. Infections are found mainly in healthy persons and 
manifest as asymptomatic or mild to moderate illness; se-
vere disease, even in immunocompromised or elderly pa-
tients, is seldom reported (2,3). B. divergens parasites are 
endemic to Europe; they are transmitted by I. ricinus ticks 
and infect bovines (4). In Europe, the disease is rare in hu-
mans; ≈40 cases have been reported (2,3,5–7). These cases 
are almost exclusively severe in immunocompromised pa-
tients, especially those whose spleens have been removed 
(2,3,8). B. divergens parasites are responsible for >70% of 
these cases (2,8), although the disease is not always con-
ﬁ  rmed by molecular-based methods.
We report 2 cases of human babesiosis in Colmar, Al-
sace, a northeastern region of France in which Lyme dis-
ease is endemic. The disease was diagnosed in spring 2009 
in healthy young persons without history of travel abroad 
who experienced a marked inﬂ  uenza-like syndrome and re-
covered. These cases should change the classic description 
of babesiosis in Europe, in which the disease was thought 
to affect immunocompromised patients exclusively. Our 
study indicates that this disease also occurs in Europe 
among immunocompetent patients.
Case Reports
Patient 1, a 37-year-old woman without known medi-
cal history, sought treatment on April 29, two weeks after 
a tick bite. She had a 38.5°C fever with chills, headaches, 
and arthromyalgia. Results of a physical examination were 
normal. Laboratory ﬁ  ndings included leukopenia (3,300 
leukocytes/μL, 45% polymorphonuclear cells, 37% lym-
phocytes), aspartate aminotransferase and alanine amin-
otransferase levels of 136 IU/L and 160 IU/L, respectively; 
γ-glutamyl transpeptidase 135 IU/L; alkaline phosphatase 
131 IU/L; and elevated C-reactive protein level (48 mg/L). 
Serologic results for Lyme disease, tick-borne encephalitis 
virus, tularemia, Anaplasma spp., Coxiella burnetii, and 
Rickettsia spp., as well as blood cultures were negative.
A thin peripheral blood smear stained with May-
Grünwald-Giemsa did not show any ehrlichial morulae in 
granulocytes, as suspected, but a retrospective examina-
tion of stored slides on May 22 (the same day that case 2 
was characterized) showed pear forms and trophozoites 
of intraerythrocytic parasites (parasitemia level 0.29%), 
leading to the diagnosis of babesiosis (Figure 1). The 
patient had initially received doxycycline (200 mg/d) 
for a suspected bacterial tick-borne infection, and her 
symptoms rapidly resolved. The ﬁ  rst blood sample was 
discarded, but on June 16 and June 24, additional serum 
and whole blood samples were collected in sodium citrate 
vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ, 
USA). The blood smears remained positive until July but 
were negative in August.
Patient 2, a 35-year-old man with an uneventful medi-
cal history, was hospitalized on May 21, two weeks after 
receiving 3 tick bites. He had a 39°C fever, severe head-
aches, and arthromyalgia. Results of a physical examina-
tion were normal. Laboratory ﬁ  ndings showed leukopenia 
(1,860 leukocytes/μL, with 35% polymorphonuclear leu-
kocytes, 49% lymphocytes), marked thrombopenia with 
36,000 platelets/mm3, elevated liver enzyme levels  (aspar-
tate aminotransferase 70 IU/L, alanine aminotransferase 
77 IU/L, γ-glutamyl transferase 161 IU/L, and alkaline 
phosphatase 86 IU/L), and elevated C-reactive protein (124 
mg/L). Tick-transmitted disease serologic results and blood 
cultures were negative.
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A thin peripheral blood smear stained with May-
Grünwald-Giemsa showed intraerythrocytic Babesia spp. 
(parasitemia level 0.23%) (Figure 2). The patient received 
azithromycin 500 mg on day 1 then 250 mg/day plus atova-
quone, and his illness rapidly resolved. Two samples of 
serum and whole blood were collected in sodium citrate 
vacutainer tubes on June 16 and July 21 and sent to the 
veterinary laboratory of Nantes for B. divergens serolog-
ic analysis (indirect immunoﬂ   uorescent assay by using 
gerbil-derived strain B. divergens Rouen F5 antigen), 
erythrocyte cultures, and DNA extraction (Wizard genomic 
DNA Puriﬁ  cation kit; Promega, Madison, WI, USA) for 
PCR Babesia spp. (9). 
Serologic results and cultures remained negative for 
both patients. However, serologic analysis is neither sensi-
tive nor speciﬁ  c (7,10), and cultures probably were inhib-
ited because blood samples were collected after doxycy-
cline or azithromycin proguanil treatments. The PCR for 
Babesia spp. is speciﬁ  c for an 18S rDNA 540-base long 
region of a variable part of the gene with Bab primers GF2 
and GR2, was performed (9,11). Results were positive for 
patient 1. The sequencing of PCR products showed 100% 
homology with B. divergens human strains GenBank ac-
cession nos. FJ944822 and FJ944823 (9). PCR results were 
negative for patient 2. Samples from patient 2 were col-
lected 1 month after treatment with atovaquone-proguanil, 
and the blood smear was negative. However, the clinical 
and biological data and the observation of trophozoites (es-
pecially 2 trophozoites in 1 erythrocyte) in the blood smear 
from patient 2 conﬁ  rmed by a reference laboratory led us 
to strongly suspect babesiosis (Figure 2). In this case, the 
Babesia species remains unknown, and a non–B. divergens 
species cannot be ruled out, although it is rarer.
Conclusions
Our cases highlight that, in Europe, babesiosis can oc-
cur in healthy persons and manifest as moderate illness. 
The rarity of other reported cases in nonimmunocompro-
mised patients in Europe may be related to the difﬁ  culty of 
diagnosing babesiosis. A stained thin blood smear is rarely 
performed in Europe after tick bite in healthy patients. The 
difﬁ  culty of detecting intra-erythrocytic forms of babesia 
coupled with frequent low levels of parasitemia, may re-
sult in accurate diagnoses, although acridine orange and 
ﬂ  uorescent microscopy may assist in the detection of para-
sites (1). Other diagnostic tests, such as PCR and serologic 
analysis, are not routinely performed in France and require 
a reference laboratory (8).
Babesiosis, although difﬁ  cult to diagnose, needs to be 
diagnosed for various reasons: 1) without treatment, babe-
siosis can lead to severe illness; 2) the disease can persist 
for a long period without symptoms, which could lead to 
posttransfusion cases (12); and 3) effective speciﬁ  c treat-
ments are available (atovaquone plus azithromycin, or for 
severe cases, clindamycin and quinine) (2). These drugs 
are not usually prescribed in febrile tick-bite cases; doxy-
cycline is the usual drug used to treat tick-borne bacterial 
diseases. Moreover, patients with moderate infection could 
beneﬁ  t from an atovaquone plus azithromycin regimen, 
which is better tolerated (13).
Previous serosurveys from tick-exposed patients or 
healthy blood donors in France (7), Germany (14), and Swit-
zerland (15) have demonstrated antibodies against Babesia 
spp. antigens ranging from 1.0% to 11.5%. These data sug-
gest that Babesia spp. infections probably occur more fre-
quently in Europe than previously believed and may affect 
healthy patients. Although most patients may be asymp-
tomatic, our 2 cases demonstrate that babesiosis can result 
in a serious inﬂ  uenza-like syndrome in previously healthy 
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Figure 1. Two trophozoites, pear-shaped, of Babesia divergens in 
erythrocytes from case-patient 1 (original magniﬁ  cation  ×1,000, 
May-Grünwald-Giemsa stain).
Figure 2. Two trophozoites of Babesia spp. in 1 erythrocyte from 
case-patient 2 (original magniﬁ  cation  ×1,000, May-Grünwald-
Giemsa stain).patients. In Europe, babesiosis is probably underdiagnosed; 
thus, we suggest that when patients have inﬂ  uenza-like or 
malaria-like syndromes after conﬁ  rmed or suspected tick 
bites, a blood smear be performed regardless of whether the 
patient is immunocompromised. Blood smear can identify 
not only Babesia spp. infection but also Anaplasma spp. 
infection, another emerging and underdiagnosed tick-borne 
illness. In cases of new European Babesia spp. infections, 
a deeper characterization of the strains by erythrocytes cul-
tures and standardized PCR, as well as a systematic study 
of the patients’ immune systems, should be undertaken to 
enable a better understanding of this disease.  
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